AI Tokens
Stock Analysis on Net

Shockwave Medical Inc. (NASDAQ:SWAV)

This company has been moved to the archive! The financial data has not been updated since May 6, 2024.

Enterprise Value to FCFF (EV/FCFF)

Microsoft Excel

Free Cash Flow to The Firm (FCFF)

Shockwave Medical Inc., FCFF calculation

US$ in thousands

Microsoft Excel
12 months ended: Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019
Net income (loss) 147,278 215,996 (9,136) (65,699) (51,109)
Net noncash charges 92,635 (40,333) 40,690 14,829 6,496
Changes in operating assets and liabilities (43,860) (57,931) (16,518) (20,314) (3,494)
Net cash provided by (used in) operating activities 196,053 117,732 15,036 (71,184) (48,107)
Interest paid, net of tax1 493 625 463 434 422
Purchase of property and equipment (30,595) (25,126) (12,439) (11,520) (3,817)
Free cash flow to the firm (FCFF) 165,951 93,231 3,060 (82,270) (51,502)

Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).


A significant positive reversal in cash flow generation is observed between 2019 and 2023. The company transitioned from a period of substantial cash consumption to a state of robust positive cash generation, with both net cash provided by operating activities and free cash flow to the firm (FCFF) exhibiting an accelerating upward trajectory.

Operating Cash Flow Evolution
Net cash provided by operating activities was negative during the 2019 and 2020 periods, reaching a low of negative 71.18 million US dollars in 2020. A pivotal shift occurred in 2021, when operating cash flow turned positive at 15.04 million US dollars. This growth accelerated sharply in subsequent years, increasing to 117.73 million US dollars in 2022 and reaching 196.05 million US dollars by the end of 2023.
FCFF Performance and Trends
Free cash flow to the firm mirrored the trajectory of operating cash flow but remained more deeply negative during the initial deficit phase, recording negative 82.27 million US dollars in 2020. The transition to positive territory occurred in 2021 with an FCFF of 3.06 million US dollars. By 2023, FCFF expanded to 165.95 million US dollars, representing a substantial increase in the firm's ability to generate cash available to all capital providers.
Analysis of Cash Flow Divergence
The variance between operating cash flow and FCFF indicates the impact of capital expenditures. In the early period (2019-2020), FCFF was more negative than operating cash flow, suggesting ongoing investment in assets. In the growth phase (2021-2023), while FCFF remained lower than operating cash flow, the absolute growth in both metrics confirms that the increase in operational efficiency is significantly outpacing the capital requirements of the business.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.

How can I help you?


Interest Paid, Net of Tax

Shockwave Medical Inc., interest paid, net of tax calculation

US$ in thousands

Microsoft Excel
12 months ended: Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019
Effective Income Tax Rate (EITR)
EITR1 73.78% 21.00% 21.00% 21.00% 21.00%
Interest Paid, Net of Tax
Interest paid, before tax 1,882 791 586 549 534
Less: Interest paid, tax2 1,389 166 123 115 112
Interest paid, net of tax 493 625 463 434 422

Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).

1 See details »

2 2023 Calculation
Interest paid, tax = Interest paid × EITR
= 1,882 × 73.78% = 1,389


The analysis of interest paid, net of tax, reveals a period of consistent growth followed by a contraction in the most recent fiscal year. From 2019 through 2022, the net interest expenditure exhibited a steady upward trajectory, increasing from 422 thousand US dollars to a peak of 625 thousand US dollars.

Interest Expenditure Trends
Between 2019 and 2022, a cumulative increase of approximately 48% in net interest paid was observed. This progression indicates a rising cost of debt service over the four-year period. This trend reversed in 2023, as the net amount decreased to 493 thousand US dollars, marking a 21.1% decline from the 2022 peak.
Correlation with Effective Income Tax Rate (EITR)
From 2019 to 2022, the effective income tax rate remained constant at 21%, suggesting that the rise in net interest paid was driven by the underlying gross interest obligations. In 2023, a significant shift occurred as the EITR increased sharply to 73.78%. This surge in the tax rate likely enhanced the tax deductibility of interest expenses, contributing to the observed reduction in the net-of-tax expenditure.
Financial Implications of Tax Volatility
The divergence observed in 2023 indicates that the decrease in net interest paid is closely linked to the volatility of the effective income tax rate. The substantial increase in the tax shield provided by the higher EITR effectively lowered the net cost of interest, regardless of the gross interest obligations incurred during the period.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.

How can I help you?


Enterprise Value to FCFF Ratio, Current

Shockwave Medical Inc., current EV/FCFF calculation, comparison to benchmarks

Microsoft Excel
Selected Financial Data (US$ in thousands)
Enterprise value (EV) 12,130,678
Free cash flow to the firm (FCFF) 165,951
Valuation Ratio
EV/FCFF 73.10
Benchmarks
EV/FCFF, Competitors1
Abbott Laboratories 25.75
Elevance Health Inc. 20.49
Intuitive Surgical Inc. 62.87
Medtronic PLC 25.42
UnitedHealth Group Inc. 20.98
EV/FCFF, Sector
Health Care Equipment & Services 20.89
EV/FCFF, Industry
Health Care 33.97

Based on: 10-K (reporting date: 2023-12-31).

1 Click competitor name to see calculations.

If the company EV/FCFF is lower then the EV/FCFF of benchmark then company is relatively undervalued.
Otherwise, if the company EV/FCFF is higher then the EV/FCFF of benchmark then company is relatively overvalued.


Enterprise Value to FCFF Ratio, Historical

Shockwave Medical Inc., historical EV/FCFF calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019
Selected Financial Data (US$ in thousands)
Enterprise value (EV)1 9,460,368 6,636,311 6,076,558 3,882,504 739,674
Free cash flow to the firm (FCFF)2 165,951 93,231 3,060 (82,270) (51,502)
Valuation Ratio
EV/FCFF3 57.01 71.18 1,985.84 — —
Benchmarks
EV/FCFF, Competitors4
Abbott Laboratories 36.51 23.24 23.47 — —
Elevance Health Inc. 14.19 13.32 12.74 — —
Intuitive Surgical Inc. 170.92 85.45 56.01 — —
Medtronic PLC 26.54 20.32 33.84 — —
UnitedHealth Group Inc. 17.59 19.30 22.21 — —
EV/FCFF, Sector
Health Care Equipment & Services 22.68 20.44 23.51 — —
EV/FCFF, Industry
Health Care 25.98 18.66 17.80 — —

Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).

1 See details »

2 See details »

3 2023 Calculation
EV/FCFF = EV ÷ FCFF
= 9,460,368 ÷ 165,951 = 57.01

4 Click competitor name to see calculations.


The financial trajectory between 2019 and 2023 is characterized by a substantial expansion in Enterprise Value (EV) and a fundamental shift in the company's ability to generate Free Cash Flow to the Firm (FCFF). The transition from negative cash flow to consistent growth indicates a move from an investment-heavy phase toward operational self-sufficiency and value realization.

Enterprise Value Trends
A consistent and aggressive increase in Enterprise Value is observed over the five-year period. EV grew from 739,674 thousand US$ in 2019 to 9,460,368 thousand US$ by 2023. The most significant leap occurred between 2019 and 2020, where the valuation increased more than fivefold, followed by steady growth through 2023.
Free Cash Flow to the Firm Performance
The company experienced a period of negative FCFF in 2019 and 2020, with the deficit peaking at -82,270 thousand US$ in 2020. A pivot occurred in 2021, as FCFF turned positive at 3,060 thousand US$. This positive trend accelerated rapidly, reaching 93,231 thousand US$ in 2022 and further increasing to 165,951 thousand US$ in 2023, demonstrating a strong capacity for generating cash relative to capital expenditures and operating costs.
EV/FCFF Ratio Analysis
The EV/FCFF ratio was not applicable during the initial years of negative cash flow. Upon the transition to positive FCFF in 2021, the ratio was exceptionally high at 1,985.84, reflecting a valuation that far exceeded current cash flow generation. However, a sharp downward trend in the ratio followed, dropping to 71.18 in 2022 and 57.01 in 2023. This compression suggests that while the valuation remains high, the growth in FCFF is outpacing the growth in Enterprise Value, leading to a more sustainable valuation multiple over time.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.

How can I help you?